SWOG clinical trial number
SWOG-8947

Central Lymphoma Serum Repository Protocol

Closed
Phase
Abbreviated Title
ANCILLARY: Central Lymphoma Serum Repository Protocol
Activated
04/15/1990
Participants
NCORP, Members, Medical Oncologists, Pathologists

Research committees

Lymphoma

Eligibility Criteria Expand/Collapse

For patients registered to a currently active Southwest Oncology Group-coordinated treatment protocol for previously untreated non-Hodgkin's lymphoma.

Publication Information Expand/Collapse

2015

Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies

J Kelly;G Salles;B Goldman;RI Fisher;O Casasnovas;O Press;DG Maloney;P Soubeyran;L Rimsza;M Leblanc;H Tilly;J Friedberg Journal of Clinical Oncology May 1;33(13):1482-1490

PMid: PMID25823738 | PMC number: PMC4404425

2012

Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation and replication in SWOG and LYSA

JL Kelly;G Salles;B Goldman;R Fisher;O Casasnovas;O Press;D Maloney;P Soubeyran;L Rimsza;M Leblanc;H Tilly;J Friedberg Blood 120(21):abst.2712; American Society of Hematology, poster;

Other Clinical Trials

SWOG Clinical Trial Number
S2308

Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma
Research Committee(s)
Lymphoma
Activated
08/01/2024
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
S2207

Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapse/Refractory Large B-Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
06/30/2023
Accrual
12%
Open
Phase
SWOG Clinical Trial Number
CTSU/AHOD2131

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Research Committee(s)
Lymphoma
Immunomolecular Therapeutics
Activated
04/28/2023
Open
Phase